This phase II trial is testing an investigational drug (INCB050465) in patients with Diffuse Large B-Cell Lymphoma that has gotten worse or is not responsive to treatment.
This trial is treating patients with Diffuse Large B-Cell Lymphoma (DLBCL).
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Commercial Sponsor
Incyte Corporation
Summary
The purpose of this study is to assess the safety and efficacy of INCB050465 in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More